Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Jun 2022
Historique:
received: 25 05 2022
revised: 16 06 2022
accepted: 20 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

SerpinA1 (α1-antitrypsin) is a soluble glycoprotein, the cerebrospinal fluid (CSF) isoforms of which showed disease-specific changes in neurodegenerative disorders that are still unexplored in Alz-heimer’s disease (AD). By means of capillary isoelectric focusing immunoassay, we investigated six serpinA1 isoforms in CSF samples of controls (n = 29), AD-MCI (n = 29), AD-dem (n = 26) and Lewy body disease (LBD, n = 59) patients and correlated the findings with CSF AD core biomarkers (Aβ42/40 ratio, p-tau, t-tau). Four CSF serpinA1 isoforms were differently expressed in AD patients compared to controls and LBD patients, especially isoforms 2 and 4. AD-specific changes were found since the MCI stage and significantly correlated with decreased Aβ42/40 (p < 0.05) and in-creased p-tau and t-tau levels in CSF (p < 0.001). Analysis of serpinA1 isoform provided good di-agnostic accuracy in discriminating AD patients versus controls (AUC = 0.80) and versus LBD patients (AUC = 0.92), with best results in patients in the dementia stage (AUC = 0.97). SerpinA1 isoform expression is altered in AD patients, suggesting a common, albeit disease-specific, in-volvement of serpinA1 in most neurodegenerative disorders.

Identifiants

pubmed: 35805926
pii: ijms23136922
doi: 10.3390/ijms23136922
pmc: PMC9266332
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
Peptide Fragments 0
Protein Isoforms 0
SERPINA1 protein, human 0
alpha 1-Antitrypsin 0
tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : EU Joint Programme-Neurodegenerative Diseases networks Genfi-Prox
ID : 01ED2008A
Organisme : German Federal Ministry of Education and Research
ID : FTLDc 01GI1007A
Organisme : EU (Moodmarker) program
ID : 01EW2008
Organisme : German Research Foundation/DFG
ID : SFB1279
Organisme : Foundation of the State Baden-Württemberg
ID : D.3830
Organisme : Boehringer Ingelheim Ulm University BioCenter
ID : D.5009
Organisme : Thierry Latran Foundation
ID : D.2468

Références

PLoS One. 2012;7(11):e48783
pubmed: 23144969
Front Immunol. 2018 May 30;9:1202
pubmed: 29899745
J Neuroinflammation. 2014 Sep 23;11:165
pubmed: 25245568
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Nat Rev Dis Primers. 2016 Jul 28;2:16051
pubmed: 27465791
J Intern Med. 2014 Oct;276(4):311-35
pubmed: 24661570
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Diagnostics (Basel). 2020 Nov 26;10(12):
pubmed: 33256252
Acta Neuropathol. 2017 Nov;134(5):715-728
pubmed: 28808785
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Mov Disord. 2012 Mar;27(3):349-56
pubmed: 22275317
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Nature. 2008 Oct 30;455(7217):1255-8
pubmed: 18923394
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Neurology. 2007 Oct 16;69(16):1569-79
pubmed: 17761554
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):6955-60
pubmed: 25971727
Biochem J. 2016 Aug 1;473(15):2273-93
pubmed: 27470592
Arch Neurol. 2009 Dec;66(12):1447-55
pubmed: 20008648
Am J Physiol Cell Physiol. 2021 Jan 1;320(1):C106-C118
pubmed: 33112643
Neurology. 2020 Jan 21;94(3):e282-e291
pubmed: 31862783
Neuroreport. 1992 Feb;3(2):201-3
pubmed: 1623174
Sci Rep. 2016 May 17;6:26145
pubmed: 27184740
J Mol Biol. 2002 Dec 6;324(4):859-70
pubmed: 12460583
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
Ann Clin Transl Neurol. 2020 Feb;7(2):191-199
pubmed: 31957347
Mov Disord. 2008 May 15;23(7):1043-1046
pubmed: 18381646

Auteurs

Lorenzo Barba (L)

Department of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Department of Neurology, Ulm University Hospital, 89081 Ulm, Germany.
Section of Neurology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.

Steffen Halbgebauer (S)

Department of Neurology, Ulm University Hospital, 89081 Ulm, Germany.

Federico Paolini Paoletti (F)

Section of Neurology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.

Giovanni Bellomo (G)

Section of Neurology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.

Samir Abu-Rumeileh (S)

Department of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.

Petra Steinacker (P)

Department of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.

Federico Massa (F)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16132 Genoa, Italy.

Lucilla Parnetti (L)

Section of Neurology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.

Markus Otto (M)

Department of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Department of Neurology, Ulm University Hospital, 89081 Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH